337506-83-9

Basic information

• Product Name: 1,1-bis(4-fluorophenyl)butane-1,4-diol
• Synonyms: 1,1-bis(4-fluorophenyl)butane-1,4-diol
• CAS NO: 337506-83-9
• Molecular Weight: 278.299
• Mol File: 337506-83-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1,1-bis(4-fluorophenyl)butane-1,4-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1-bis(4-fluorophenyl)butane-1,4-diol(337506-83-9)
• EPA Substance Registry System: 1,1-bis(4-fluorophenyl)butane-1,4-diol(337506-83-9)

Safety Data

• Hazardous Substances Data: 337506-83-9(Hazardous Substances Data)

Upstream product

• 293729-65-4 5,5-bis-(4-fluoro-phenyl)-tetrahydro-furan-2-ol 
• 357-77-7 1,1-bis(4-fluorophenyl)prop-2-yn-1-ol 
• 99734-06-2 α,α-bis(4-fluorophenyl)allyl alcohol 
• 96-48-0 4-butanolide 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 352-13-6 4-flourophenylmagnesium bromide 
• 345-92-6 4,4'-Difluorobenzophenone 

Downstream Products

• 50337-85-4 4,4-bis(4-fluorophenyl)butan-1-ol 
• 26864-56-2 penfluridol 
• 57668-61-8 4,4'-(4-bromobutane-1,1-diyl)bis(fluorobenzene) 
• 1841-19-6 fluspirilene 
• 59455-11-7 1-[4-bromo-1-(4-fluorophenyl)but-1-en-1-yl]-4-fluorobenzene 
• 64630-52-0 4,4-bis-(4-fluoro-phenyl)-butylamine 
• 1841-17-4 8-[4,4-bis(4-fluorophenyl)-but-3-enyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 
• 20662-52-6 4,4-bis(4-fluorophenyl)butanoic acid 
• 1266656-43-2 8-(4,4-bis(4-fluorophenyl)butanoyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 

Relevant articles and documents

Fluspirilene Analogs Activate the 20S Proteasome and Overcome Proteasome Impairment by Intrinsically Disordered Protein Oligomers

Oligomerization of aggregation-prone intrinsically disordered proteins (IDPs), such as α-synuclein, amyloid β, and tau, has been shown to be associated with the pathogenesis of several neurodegenerative diseases, including Parkinson's and Alzheimer's disease. The proteasome is charged with regulating cellular levels of IDPs, but this degradation pathway can become dysregulated leading to their accumulation and subsequent aggregation. Although the pathogenesis of these neurodegenerative diseases is still under intense investigation, it has been shown that the oligomeric forms of IDPs, including α-synuclein and amyloid β, can impair proteasome function. This leads to additional accumulation of the IDPs, further promoting disease progression. Herein, we report the use of small molecule activators of the 20S subcomplex of the proteasome to restore impaired 20S proteasome activity and prevent IDP accumulation and oligomerization. We found that fluspirilene and its new synthetic analog (16) show strong 20S proteasome enhancement (doubling 20S proteolytic activity at μ2 μM, with maximum fold enhancement of μ1000%), overcome impaired proteasome function, and prevent the accumulation of pathogenic IDPs. These findings provide support for the use of 20S enhancers as a possible therapeutic strategy to combat neurodegenerative diseases.

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.

Rhodium catalyzed hydroformylation of 1,1-bis(p-fluorophenyl)allyl or propargyl alcohol: A key step in the synthesis of Fluspirilen and Penfluridol

Fluspirilen (1) and Penfluridol (2), two neuroleptic agents, belong to a wide class of pharmaceuticals that contain in their molecules a 4,4-bis(p-fluorophenyl)butyl group bound to a nitrogen atom of a pyrrolidine, piperidine or piperazine moiety. A key intermediate for the synthesis of compounds 1 and 2,4,4-bis(p-fluorophenyl)butylbromide (15), has been prepared starting from commercially available 4,4′-difluorobenzophenone (7) following a preparative route involving the rhodium catalyzed hydroformylation in toluene or in the biphasic system toluene/water or cyclohexane/water of 1,1-bis(p-fluorophenyl)-2-propenol (8) and/or 1,1-bis(p-fluorophenyl)-2-propynol (12). Fluspirilen and Penfluridol were obtained in 70-80% yield by reaction of bromide 15 with 1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one (16) and 4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol (17), respectively. The overall yields of the two pharmaceuticals 1 and 2, based on starting ketone 7, were about 35-40%.